vs
Cytek Biosciences, Inc.（CTKB）与弗雷斯特研究公司（FORR）财务数据对比。点击上方公司名可切换其他公司
弗雷斯特研究公司的季度营收约是Cytek Biosciences, Inc.的1.6倍（$101.1M vs $62.1M），弗雷斯特研究公司净利率更高（-33.5% vs -70.9%，领先37.4%），Cytek Biosciences, Inc.同比增速更快（8.1% vs -6.5%），Cytek Biosciences, Inc.自由现金流更多（$-1.8M vs $-4.3M），过去两年Cytek Biosciences, Inc.的营收复合增速更高（17.7% vs 0.5%）
Cytek Biosciences主营高性能流式细胞分析系统、配套试剂及分析软件的研发、生产与商业化，产品服务覆盖生命科学研究、临床诊断、生物制药开发等领域，客户遍及全球多个主要地区。
福雷斯特研究公司是一家全球领先的研究咨询机构，主营业务涵盖行业研究、管理咨询与行业峰会举办，客户群体包括全球大型企业、科技公司与消费领域领军企业，公司总部位于美国马萨诸塞州剑桥市。
CTKB vs FORR — 直观对比
营收规模更大
FORR
是对方的1.6倍
$62.1M
营收增速更快
CTKB
高出14.6%
-6.5%
净利率更高
FORR
高出37.4%
-70.9%
自由现金流更多
CTKB
多$2.5M
$-4.3M
两年增速更快
CTKB
近两年复合增速
0.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $62.1M | $101.1M |
| 净利润 | $-44.1M | $-33.9M |
| 毛利率 | 52.9% | 56.7% |
| 营业利润率 | -9.0% | -36.6% |
| 净利率 | -70.9% | -33.5% |
| 营收同比 | 8.1% | -6.5% |
| 净利润同比 | -557.1% | -7941.4% |
| 每股收益（稀释后） | — | $-1.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTKBFORR
| Q4 25 | $62.1M | $101.1M | ||
| Q3 25 | $52.3M | $94.3M | ||
| Q2 25 | $45.6M | $111.7M | ||
| Q1 25 | $41.5M | $89.9M | ||
| Q4 24 | $57.5M | $108.0M | ||
| Q3 24 | $51.5M | $102.5M | ||
| Q2 24 | $46.6M | $121.8M | ||
| Q1 24 | $44.9M | $100.1M |
净利润CTKBFORR
| Q4 25 | $-44.1M | $-33.9M | ||
| Q3 25 | $-5.5M | $-2.1M | ||
| Q2 25 | $-5.6M | $3.9M | ||
| Q1 25 | $-11.4M | $-87.3M | ||
| Q4 24 | $9.6M | $432.0K | ||
| Q3 24 | $941.0K | $-5.8M | ||
| Q2 24 | $-10.4M | $6.3M | ||
| Q1 24 | $-6.2M | $-6.7M |
毛利率CTKBFORR
| Q4 25 | 52.9% | 56.7% | ||
| Q3 25 | 52.7% | 60.0% | ||
| Q2 25 | 52.3% | 55.5% | ||
| Q1 25 | 48.6% | 55.9% | ||
| Q4 24 | 58.5% | 58.8% | ||
| Q3 24 | 56.3% | 60.5% | ||
| Q2 24 | 54.6% | 57.3% | ||
| Q1 24 | 51.3% | 54.9% |
营业利润率CTKBFORR
| Q4 25 | -9.0% | -36.6% | ||
| Q3 25 | -17.6% | 4.7% | ||
| Q2 25 | -23.3% | 6.2% | ||
| Q1 25 | -36.1% | -97.5% | ||
| Q4 24 | 5.2% | -0.5% | ||
| Q3 24 | -8.2% | -0.7% | ||
| Q2 24 | -18.3% | 9.3% | ||
| Q1 24 | -23.9% | -9.3% |
净利率CTKBFORR
| Q4 25 | -70.9% | -33.5% | ||
| Q3 25 | -10.5% | -2.3% | ||
| Q2 25 | -12.2% | 3.5% | ||
| Q1 25 | -27.5% | -97.1% | ||
| Q4 24 | 16.8% | 0.4% | ||
| Q3 24 | 1.8% | -5.7% | ||
| Q2 24 | -22.4% | 5.2% | ||
| Q1 24 | -13.8% | -6.7% |
每股收益（稀释后）CTKBFORR
| Q4 25 | — | $-1.75 | ||
| Q3 25 | — | $-0.11 | ||
| Q2 25 | — | $0.20 | ||
| Q1 25 | — | $-4.62 | ||
| Q4 24 | — | $0.02 | ||
| Q3 24 | — | $-0.30 | ||
| Q2 24 | — | $0.33 | ||
| Q1 24 | — | $-0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $90.9M | $63.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $341.7M | $126.5M |
| 总资产 | $461.5M | $404.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CTKBFORR
| Q4 25 | $90.9M | $63.3M | ||
| Q3 25 | $93.3M | $65.1M | ||
| Q2 25 | $75.5M | $67.8M | ||
| Q1 25 | $95.3M | $75.6M | ||
| Q4 24 | $98.7M | $56.1M | ||
| Q3 24 | $162.3M | $62.8M | ||
| Q2 24 | $177.9M | $58.9M | ||
| Q1 24 | $168.8M | $61.4M |
股东权益CTKBFORR
| Q4 25 | $341.7M | $126.5M | ||
| Q3 25 | $378.6M | $157.7M | ||
| Q2 25 | $377.6M | $159.5M | ||
| Q1 25 | $379.6M | $147.4M | ||
| Q4 24 | $395.7M | $229.5M | ||
| Q3 24 | $385.5M | $234.3M | ||
| Q2 24 | $389.1M | $237.1M | ||
| Q1 24 | $392.6M | $230.9M |
总资产CTKBFORR
| Q4 25 | $461.5M | $404.0M | ||
| Q3 25 | $494.9M | $414.2M | ||
| Q2 25 | $493.3M | $436.0M | ||
| Q1 25 | $482.6M | $439.8M | ||
| Q4 24 | $499.5M | $503.9M | ||
| Q3 24 | $491.2M | $505.3M | ||
| Q2 24 | $483.7M | $524.2M | ||
| Q1 24 | $492.1M | $555.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-771.0K | $-3.2M |
| 自由现金流经营现金流 - 资本支出 | $-1.8M | $-4.3M |
| 自由现金流率自由现金流/营收 | -2.9% | -4.2% |
| 资本支出强度资本支出/营收 | 1.6% | 1.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-8.8M | $18.1M |
8季度趋势，按日历期对齐
经营现金流CTKBFORR
| Q4 25 | $-771.0K | $-3.2M | ||
| Q3 25 | $-3.9M | $1.2M | ||
| Q2 25 | $108.0K | $-3.6M | ||
| Q1 25 | $-125.0K | $26.7M | ||
| Q4 24 | $2.0M | $-1.8M | ||
| Q3 24 | $13.2M | $264.0K | ||
| Q2 24 | $6.2M | $-2.9M | ||
| Q1 24 | $4.0M | $611.0K |
自由现金流CTKBFORR
| Q4 25 | $-1.8M | $-4.3M | ||
| Q3 25 | $-4.6M | $524.0K | ||
| Q2 25 | $-1.5M | $-4.2M | ||
| Q1 25 | $-974.0K | $26.1M | ||
| Q4 24 | $1.1M | $-2.5M | ||
| Q3 24 | $12.2M | $-223.0K | ||
| Q2 24 | $5.2M | $-3.7M | ||
| Q1 24 | $3.4M | $-815.0K |
自由现金流率CTKBFORR
| Q4 25 | -2.9% | -4.2% | ||
| Q3 25 | -8.7% | 0.6% | ||
| Q2 25 | -3.2% | -3.8% | ||
| Q1 25 | -2.3% | 29.0% | ||
| Q4 24 | 1.9% | -2.3% | ||
| Q3 24 | 23.7% | -0.2% | ||
| Q2 24 | 11.0% | -3.1% | ||
| Q1 24 | 7.6% | -0.8% |
资本支出强度CTKBFORR
| Q4 25 | 1.6% | 1.1% | ||
| Q3 25 | 1.3% | 0.7% | ||
| Q2 25 | 3.5% | 0.5% | ||
| Q1 25 | 2.0% | 0.7% | ||
| Q4 24 | 1.6% | 0.6% | ||
| Q3 24 | 2.0% | 0.5% | ||
| Q2 24 | 2.3% | 0.7% | ||
| Q1 24 | 1.3% | 1.4% |
现金转化率CTKBFORR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.93× | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | -4.24× | ||
| Q3 24 | 14.05× | — | ||
| Q2 24 | — | -0.46× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
FORR
| Research Segment | $82.2M | 81% |
| Consulting Segment | $16.2M | 16% |
| Billable Expenses | $1.5M | 2% |
| Professional Services | $1.4M | 1% |
